Ordinary Index Rebalancing in the Solactive China Biotech Index | January 2020
In the ordinary rebalance the following composition will be implemented:
| 3SBIO INC | 3.4236 % |
| BEIGENE LTD-ADR | 6.0 % |
| BEIJING TIANTAN BIOLOGICAL-A | 3.0833 % |
| BETTA PHARMACEUTICALS CO L-A | 6.0 % |
| BGI GENOMICS CO LTD-A | 6.0 % |
| CHINA BIOLOGIC PRODUCTS HOLD | 4.535 % |
| GENSCRIPT BIOTECH CORP | 5.3912 % |
| HANSOH PHARMACEUTICAL GROUP CO | 5.6628 % |
| HUALAN BIOLOGICAL ENGINEER-A | 6.0 % |
| HUTCHISON CHINA MEDITECH-ADR | 3.5614 % |
| INNOVENT BIOLOGICS INC | 6.0 % |
| JIANGSU HENGRUI MEDICINE CO LTD CLASS A | 6.0 % |
| LIVZON PHARMACEUTICAL GROU-A | 3.5062 % |
| NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO LTD | 1.8099 % |
| SHANGHAI RAAS BLOOD PRODUC-A | 3.0266 % |
| SHENZHEN KANGTAI BIOLOGICA-A | 6.0 % |
| SINO BIOPHARMACEUTICAL LTD ORD | 6.0 % |
| WALVAX BIOTECHNOLOGY CO-A | 6.0 % |
| WUXI APPTEC CO LTD-A | 6.0 % |
| WUXI BIOLOGICS CAYMAN INC | 6.0 % |